Lugen SCI

Lugen Sci is a South Korean biotechnology company dedicated to the discovery and development of innovative therapeutics using Targeted Protein Degradation (TPD) technology. The company utilizes its proprietary PROTAC platform to design small molecules that selectively degrade disease-causing proteins, particularly those previously considered undruggable. Their primary focus is on oncology, with a pipeline targeting the androgen receptor for prostate cancer and the estrogen receptor for breast cancer. By addressing mechanisms of drug resistance, Lugen Sci aims to provide more effective treatment options for patients with advanced cancers. The company is also expanding its research into immunology and other therapeutic areas where protein degradation can offer clinical benefits. Founded in 2019, Lugen Sci has secured significant venture capital funding to advance its lead programs toward clinical trials.